Life Sciences & Biotechnology
Title : | Targeted nano-immunochemotherapeutic for improved triple-negative breast cancer therapy |
Area of research : | Life Sciences & Biotechnology |
Focus area : | Medical Sciences |
Principal Investigator : | Ms. Nagma Banjare, CSIR-Indian Institute Of Integrative Medicine, Jammu, Jammu And Kashmir (180001) |
Timeline Start Year : | 2024 |
Timeline End Year : | 2027 |
Contact info : | banjarenagma@gmail.com |
Details
Executive Summary : | Triple-negative breast cancers (TNBC) are the most aggressive subtype, accounting for about 15% of all breast cancers. TNBC has a high prevalence in central India, accounting for 43% of all breast cancers. Doxorubicin is the most effective chemotherapeutic for TNBC treatment, but it has shown inadequate response, toxicity, and drug resistance. Nanotechnology, particularly liposome-based drug delivery systems, can improve drug pharmacokinetics and reduce toxicity. Pegylated liposomal Doxil has shown clinical success, but its anti-cancer efficacy has not improved significantly. Monotherapy treatment approach has compromising effectiveness due to tumor cell heterogeneity, acquired chemo-resistance, and relapse. Combining two or more drugs with different modes of action is considered more effective. Recently, immunotherapy is gaining interest alongside chemotherapy, with tumor-associated macrophages (TAMs) playing a major barrier in the tumor microenvironment. Targeted liposome nanocarrier-based strategies can address these issues by targeting tumor cells and M2 TAMs. This project aims to synthesize mannose-conjugated lipids, develop and characterize mannose-modified liposomes for DOX and resiquimod, investigate drug-loaded liposome-mediated cellular uptake, macrophage repolarization, and anti-tumor efficacy, and evaluate targeted liposomal formulations for reduced cardiotoxicity and systemic cytokine release. |
Total Budget (INR): | 20,21,760 |
Organizations involved